DOCSLIB.ORG

For Flexible Modular Assembly of Golden Gate-Compatible Vectors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For Flexible Modular Assembly of Golden Gate-Compatible Vectors bioRxiv preprint doi: https://doi.org/10.1101/392423; this version posted August 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A Bacterial Expression Vector Archive (BEVA) for flexible modular 2 assembly of Golden Gate-compatible vectors 3 4 5 Barney A. Geddes*, Marcela A. Mendoza-Suárez*, Philip S. Poole# 6 7 Department of Plant Sciences, University of Oxford, Oxford, UK. 8 9 10 Running Head: Modular assembly of bacterial vectors 11 12 *These authors contributed equally to this work 13 # Address correspondence to: Philip Poole, [email protected] 14 15 1 bioRxiv preprint doi: https://doi.org/10.1101/392423; this version posted August 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 16 ABSTRACT We present a Bacterial Expression Vector Archive (BEVA) for the 17 modular assembly of bacterial vectors compatible with both traditional and 18 Golden Gate cloning, utilizing the Type IIS restriction enzyme Esp3I. Ideal for 19 synthetic biology and other applications, this modular system allows a rapid, low- 20 cost assembly of new vectors tailored to specific tasks. To demonstrate the 21 potential of the system three example vectors were constructed and tested. Golden 22 Gate level 1 vectors; pOGG024, with a broad-host range and high copy number 23 was used for gene expression in laboratory-cultured Rhizobium leguminosarum, 24 and pOGG026, with a broad-host range a lower copy number and excellent 25 stability, even in the absence of antibiotic selection. The application of pOGG026 26 is demonstrated in environmental samples by bacterial gene expression in 27 nitrogen-fixing nodules on pea plants roots formed by R. leguminosarum. Finally, 28 the level 2 cloning vector pOGG216 is a broad-host range, medium copy number, 29 for which we demonstrate an application by constructing a dual reporter plasmid 30 expressing green and red fluorescent proteins. 31 32 IMPORTANCE Modular assembly is powerful as it allows easy combining of 33 different components from a library of parts. In designing a modular vector 34 assembly system, the key constituent parts (and modules) are; an origin of 35 plasmid replication, antibiotic resistance marker(s), cloning site(s), together with 36 additional accessory modules as required. In an ideal vector, the size of each 37 module would be minimized, and this we have addressed. We have designed such 38 a vector assembly system by utilizing the Type IIS restriction enzyme Esp3I and 2 bioRxiv preprint doi: https://doi.org/10.1101/392423; this version posted August 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 39 have demonstrated its use for Golden Gate cloning in Escherichia coli. An 40 important attribute of this modular vector assembly is that using the principles 41 outlined here, new modules for specific applications, e.g. origin of replication for 42 plasmids in other bacteria, can easily be designed. It is hoped that this vector 43 construction system will be expanded by the scientific community over time by 44 creation of novel modules through an open source approach. 45 46 KEYWORDS Golden Gate, level 1, level 2, modular assembly, cloning vector, 47 shuttle vector, broad host-range plasmid, open source, plasmid design. 3 bioRxiv preprint doi: https://doi.org/10.1101/392423; this version posted August 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 48 Over the last decade, synthetic biology has emerged as a powerful tool for 49 biotechnology and basic science research (1). Coupled with rapidly improving 50 DNA synthesis technologies, one of the key advances that has potentiated the 51 rapid expansion of synthetic biology is new DNA assembly technologies (2). The 52 ability for synthetic biologists to rapidly assemble and test new designs at low 53 cost is invaluable to progress in a wide-range of life sciences research. 54 Applications for this range from investigating new antibody production with 55 higher success rates, to increased food production minimizing the carbon footprint 56 with the effective transfer of nitrogen fixation between bacterial species (3). 57 Golden Gate cloning is a DNA assembly technology that utilizes type IIS 58 restriction enzymes to assemble multiple fragments of DNA in a linear order (4). 59 Since type IIS restriction endonucleases cleave outside of their recognition site, 60 the nucleotides in the cut-site of the enzyme are not discriminated and can be 61 tailored to suit. This permits assembly of multiple fragments of DNA in a 62 directional, linear order by using unique cut/ligation sites between each fragment, 63 all of which can be cut by the same type IIS restriction enzyme. The two most 64 commonly used Golden Gate enzymes are BsaI and BpiI, each has a 6 base-pair 65 (bp) recognition site and a 4 bp sticky-end cut site (4) . The ability of these 66 enzymes to cleave outside of their recognition site and careful design of 67 compatible overhanging sequences allows repeated rounds of cutting followed by 68 ligation to proceed towards a stable assembly product which remains undigested 69 as it lacks enzyme recognition sites (due to the inward orientation of the type IIS 70 recognition sites at the far 5’ and 3’ ends of modules) (5). This approach has 4 bioRxiv preprint doi: https://doi.org/10.1101/392423; this version posted August 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 71 given a massive improvement in the efficiency of assembly compared to 72 traditional rounds of restriction/ligation cloning and has been used to assemble at 73 least nine fragments in linear order, with 90% of transformed bacterial colonies 74 containing correct products (5). 75 Golden Gate cloning platforms have been developed for plants, fungi and 76 the bacterium Escherichia coli (6–9). However, in a wide-range of bacteria, 77 vectors for cloning using Golden Gate tools are not available. The ability to use 78 the most up-to-date molecular tools is crucially important for agricultural 79 biotechnology. Here we describe the development of a system for modular 80 assembly of Golden Gate-compatible cloning broad-host range vectors from a 81 library of vector parts. As these vectors are able to replicate in E. coli, this 82 facilitates easy genetic manipulation since following plasmid construction, as the 83 plasmids constructed can be transferred easily to other bacterial species. We 84 demonstrate the efficacy of this system by constructing several vectors, analogous 85 to useful traditional cloning broad-host range vectors but that are now Golden 86 Gate-compatible: level 1 cloning broad-host range vectors pOGG024, a medium 87 copy plasmid for gene expression for in vitro grown bacteria, and pOGG026, a 88 low copy number stable vectors for stable environmental gene expression in 89 environmental samples where no antibiotic selection is applied. We also describe 90 the construction through this modular vector system of a level 2 broad-host range 91 vector pOGG216. 92 93 RESULTS AND DISCUSSION 5 bioRxiv preprint doi: https://doi.org/10.1101/392423; this version posted August 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 94 Modular vector assembly. A new standardized system for vector assembly was 95 designed based on Golden Gate cloning and the MoClo system described by 96 Weber et al. 2011 (4). We have designed a bacterial vector assembly system with 97 a series of discrete key modules. In order to do this we took advantage of the 98 modularization and miniaturization of bacterial vector modules in the Standard 99 European Vector Archive (SEVA) (10, 11). In SEVA these modules are arranged 100 in a predefined order and assembled using standard restriction enzymes and 101 standard restriction/ligation reactions. We have conserved this organization in the 102 modular vector assembly system: position 1 is the cloning site(s), position 2 is the 103 antibiotic resistance cassette, position 3 is origins of replication and transfer. 104 Three more positions (4 to 6) have been reserved for additional accessory 105 modules for specific applications. Endlinkers containing terminators (ELT) are 106 used to circularize the plasmid by connecting the final position used to position 1 107 (Fig. 1A). We incorporated Golden Gate level 1 and level 2 cloning sites into 108 position 1 to make them compatible with the MoClo Golden Gate cloning system 109 (Fig. 1B). Each vector construction module is flanked with inward-facing 110 recognition sites for the type IIS restriction enzyme Esp3I and the cut sites, giving 111 overhangs with sequences specific for each module (fusion sites shown in Table 112 1), allow directional linear assembly in a one-pot reaction such as used in Golden 113 Gate cloning (4). 114 115 Vector module design. We assigned modules a universal position for linear 116 assembly based on function; position 1 - cloning site(s), position 2 - antibiotic 6 bioRxiv preprint doi: https://doi.org/10.1101/392423; this version posted August 16, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
Load more

Recommended publications
  • Sars-Cov-2 Infection in Healthcare Workers and Their Household Contacts at the University of North Carolina Medical Center
    VECTOR OR VICTIM: SARS-COV-2 INFECTION IN HEALTHCARE WORKERS AND THEIR HOUSEHOLD CONTACTS AT THE UNIVERSITY OF NORTH CAROLINA MEDICAL CENTER Team Co-PIs: Ross Boyce, MD (SOM) and Allison Aiello, PhD (SPH) Coinvestigators: David Richardson, PhD (SPH), David Weber, MD (SOM), Emily Sickbert-Bennett, PhD, MS (SOM), Erica Pettigrew Md, JD, MPH (SOM), Raquel Reyes, MD (Hospital Medicine), Naseem Alavian, MD (Hospital Medicine), Jon Juliano, MD, MPH (SOM) Emily Ciccone MD,MHS (SOM), Billy Fischer, MD (SOM) and Subha Sellers, MD,MSc (SOM) The COVID-19 pandemic now accounts for more than 1.1 million confirmed infections and nearly than 70,000 deaths in the United States (US), along with unprecedented disruption to social networks and economic systems. The causative agent, the SARS-CoV-2 coronavirus, is primarily spread from person-to-person through the inhalation or direct contact with aerosolized droplets. Frontline healthcare workers (HCW) are at increased risk of infection due to frequent exposure to and close contact with infected patients and contaminated surfaces. Shortages of critical personal protective equipment (PPE) may further exacerbate this risk. A review of the epidemiological data from the site of the initial COVID-19 outbreak in Wuhan, China showed that 63% of HCWs were infected with SARS- CoV-2, many of who developed severe disease. While data from US facilities is still emerging, an analysis of case reports submitted to the Centers for Disease Control and Prevention (CDC) found nearly 10,000 cases of COVID-19 among HCWs. Infected HCWs can also contribute to disease transmission, both in the hospital setting and in the community.
    [Show full text]
  • Climate Change and Vector-Borne/Zoonotic Diseases
    Climate Change and Vector-Borne/Zoonotic Diseases Kenneth L. Gage Division of Vector-Borne Infectious Diseases National Center for Zoonotic, Vector-Borne and Enteric Diseases Centers for Disease Control and Prevention Vector Disease agents Threshold for Effects of Climatic Factors Biological Activity on Hosts and Vectors* Anopheles Plasmodium sp. 8-10o C mosquitoes • Growth, development and reproduction Triatomine Trypanosoma 20o C – Q10 effects (approximate doubling of bugs cruzi (2-6o C for survival) metabolic rates in poikliothermic organisms with 10oC rise in temperatures) Aedes Dengue virus 6-10o C – Rate of reproduction/Number of mosquitoes generations per season – Example: Anopheles gambiae gonotrophic Ixodes ticks Borrelia 5-8o C cycles significantly shorter in open treeless burdgdorferi, sites (warmer) than forested sites (cooler) Anaplasma • Activity patterns phagocytophilum, – Feeding Babesia microti – Host seeking o – Mate seeking etc. Bulinus and Schistosoma sp. 5 C o • Availability of breeding sites other snails (25+2 C optimal) • Survival – Severe weather events Source: Patz and Olson 2006 – Tolerance limits for vectors and hosts – Food or water availability – Freezing or heat stress Effect of Temperature on Oxygen Consumption * See Gubler et al. 2001 for citations and additional examples Climate Effects on Hosts and Vectors - Distribution and Abundance - • “Weather school” (Andrewartha and Birch 1954) – Changing conditions make areas more or less suitable for survival and reproduction, which affects abundance of different species – Changing conditions often related to climatic variables (temperature, precipitation, humidity, etc.) – Most extreme effects seen for insects and other arthropods • Host or vector populations can increase during favorable conditions and later crash as conditions deteriorate • Many examples with epidemiologic significance – Mosquito vectors • Rift valley fever (arbovirus)(Linthicum et al.
    [Show full text]
  • A National Public Health Framework for the Prevention and Control of Vector-Borne Diseases in Humans
    A National Public Health Framework for the Prevention and Control of Vector-Borne Diseases in Humans WWW.CDC.GOV/VECTOR 1 Amblyomma maculatum Publication and Copyright Information Centers for Disease Control and Prevention A National Public Health Framework for the Prevention and Control of Vector-Borne Diseases in Humans Atlanta, Georgia: September 2020 www.cdc.gov/vector Media inquiries: 404-639-3286 (9:00 am–6:00 pm ET); [email protected] Acknowledgement: Layout and graphics provided by CDC’s Creative Services. Cover Clockwise from top right: • Blacklegged tick (Ixodes scapularis), James Gathany photographer • Aedes aegypti mosquito, James Gathany photographer • Illustration of the United States • Oriental rat flea Xenopsylla( cheopsis), James Gathany photographer Accessible Version: www.cdc.gov/ncezid/dvbd/framework.html 2 A NATIONAL PUBLIC HEALTH FRAMEWORK FOR THE PREVENTION AND CONTROL OF VECTOR-BORNE DISEASES IN HUMANS Introduction and Scope Our nation’s ability to defend against the present the U.S. population from these diseases, five federal and future threat of vector-borne diseases relies on a departments and the Environmental Protection Agency comprehensive national system that is able to detect, contributed to developing a national framework for vector- prevent, and respond to these threats. A concerted borne disease prevention and control. These federal and sustained effort is needed to address significant partners represent the primary federal departments and challenges and reverse the upward trends in illness, agencies engaged
    [Show full text]
  • Chapter 2 Disease and Disease Transmission
    DISEASE AND DISEASE TRANSMISSION Chapter 2 Disease and disease transmission An enormous variety of organisms exist, including some which can survive and even develop in the body of people or animals. If the organism can cause infection, it is an infectious agent. In this manual infectious agents which cause infection and illness are called pathogens. Diseases caused by pathogens, or the toxins they produce, are communicable or infectious diseases (45). In this manual these will be called disease and infection. This chapter presents the transmission cycle of disease with its different elements, and categorises the different infections related to WES. 2.1 Introduction to the transmission cycle of disease To be able to persist or live on, pathogens must be able to leave an infected host, survive transmission in the environment, enter a susceptible person or animal, and develop and/or multiply in the newly infected host. The transmission of pathogens from current to future host follows a repeating cycle. This cycle can be simple, with a direct transmission from current to future host, or complex, where transmission occurs through (multiple) intermediate hosts or vectors. This cycle is called the transmission cycle of disease, or transmission cycle. The transmission cycle has different elements: The pathogen: the organism causing the infection The host: the infected person or animal ‘carrying’ the pathogen The exit: the method the pathogen uses to leave the body of the host Transmission: how the pathogen is transferred from host to susceptible person or animal, which can include developmental stages in the environment, in intermediate hosts, or in vectors 7 CONTROLLING AND PREVENTING DISEASE The environment: the environment in which transmission of the pathogen takes place.
    [Show full text]
  • Data–Model Fusion to Better Understand Emerging Pathogens and Improve Infectious Disease Forecasting
    July 2011 DATA ASSIMILATION FOR ECOLOGICAL FORECASTING Ecological Applications, 21(5), 2011, pp. 1443–1460 Ó 2011 by the Ecological Society of America Data–model fusion to better understand emerging pathogens and improve infectious disease forecasting 1,5 2 3 4 1 SHANNON L. LADEAU, GREGORY E. GLASS, N. THOMPSON HOBBS, ANDREW LATIMER, AND RICHARD S. OSTFELD 1Cary Institute of Ecosystem Studies, Millbrook, New York 12545 USA 2Johns Hopkins School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, Maryland 21205 USA 3Colorado State University, Natural Resource Ecology Laboratory and Graduate Degree Program in Ecology, Fort Collins, Colorado 80524 USA 4University of California, Department of Plant Sciences, Davis, California 95616 USA Abstract. Ecologists worldwide are challenged to contribute solutions to urgent and pressing environmental problems by forecasting how populations, communities, and ecosystems will respond to global change. Rising to this challenge requires organizing ecological information derived from diverse sources and formally assimilating data with models of ecological processes. The study of infectious disease has depended on strategies for integrating patterns of observed disease incidence with mechanistic process models since John Snow first mapped cholera cases around a London water pump in 1854. Still, zoonotic and vector-borne diseases increasingly affect human populations, and methods used to successfully characterize directly transmitted diseases are often insufficient. We use four case studies to demonstrate that advances in disease forecasting require better understanding of zoonotic host and vector populations, as well of the dynamics that facilitate pathogen amplification and disease spillover into humans. In each case study, this goal is complicated by limited data, spatiotemporal variability in pathogen transmission and impact, and often, insufficient biological understanding.
    [Show full text]
  • Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis
    processes Article Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis Rafael G. Ferreira 1,* , Neal F. Gordon 2, Rick Stock 2 and Demetri Petrides 3 1 Intelligen Brasil, Sao Paulo 01227-200, Brazil 2 BDO USA, LLP, Boston, MA 02110, USA; [email protected] (N.F.G.); [email protected] (R.S.) 3 Intelligen, Inc., Scotch Plains, NJ 07076, USA; [email protected] * Correspondence: [email protected] Abstract: The COVID-19 pandemic has motivated the rapid development of numerous vaccines that have proven effective against SARS-CoV-2. Several of these successful vaccines are based on the adenoviral vector platform. The mass manufacturing of these vaccines poses great challenges, especially in the context of a pandemic where extremely large quantities must be produced quickly at an affordable cost. In this work, two baseline processes for the production of a COVID-19 adenoviral vector vaccine, B1 and P1, were designed, simulated and economically evaluated with the aid of the software SuperPro Designer. B1 used a batch cell culture viral production step, with a viral titer of 5 × 1010 viral particles (VP)/mL in both stainless-steel and disposable equipment. P1 used a perfusion cell culture viral production step, with a viral titer of 1 × 1012 VP/mL in exclusively disposable equipment. Both processes were sized to produce 400 M/yr vaccine doses. P1 led to a smaller cost per dose than B1 ($0.15 vs. $0.23) and required a much smaller capital investment ($126 M vs. $299 M). The media and facility-dependent expenses were found to be the main contributors to the operating cost.
    [Show full text]
  • STD (Sexually Transmitted Disease) Or STI (Sexually Transmitted Infection): Should We Choose? Janet Byron Anderson, Phd
    STD (sexually transmitted disease) or STI (sexually transmitted infection): Should we choose? Janet Byron Anderson, PhD 1. Clinical foundation of the problem Another surprise: Documented incidence had shown Each of the terms—“sexual(ly)”, “transmitted”, “disease”, that the two routes of sexual transmission were male-to- and “infection”—is problematic independently, as this female and male-to-male. However, on 15 July 2016 the study will show. Moreover, co-occurring variants, used CDC reported the first case of suspected female-to-male as synonyms in English medical articles worldwide, ag- sexual transmission in New York City [4]. Since 2008, gravate the problem. The purpose of this study is to pro- then, the Zika virus has shown that it is now sexually pose a single term that can stimulate discussion about transmissible. “Transmissible” denotes a potential, and is whether the co-occurring variants are clinically and lin- distinct from “transmitted”, which denotes a reality. guistically justifiable—especially now, when STDs/STIs To say that Zika has proved to be transmissible through have become a global health problem, and public health sexual contact means that it can be transmitted through agencies in every country are scrambling to educate their sex but that it need not be (Zika remains a chiefly vec- citizens. [Until the presentation advances to the point tor-borne disease). However, cases reported since 2008 where the question posed in the title can be definitively document the reality of transmittedness through sexual answered, I’ll use the expression “STD/STI” or the terms contact. “illness(es)” and “condition(s)”.] The predisposing epidemiologic context will first be clar- This carefully differentiated language is used by the ified, for it sheds light on two of the problematic terms: European Centre for Disease Prevention and Control chiefly “transmitted” but also “sexual(ly)”.
    [Show full text]
  • GIPZ™ Lentiviral Shrna
    TECHNICAL MANUAL GIPZ™ Lentiviral shRNA Product description Design information The Dharmacon™ GIPZ™ Lentiviral shRNA Library was developed in collabora- Unique microRNA-30 based hairpin design tion with Dr. Greg Hannon of Cold Spring Harbor Laboratory [CSHL] and Dr. Short hairpin RNA (shRNA) constructs are expressed as human microRNA-30 Steve Elledge of Harvard Medical School. This library combines the design (miR-30) primary transcripts. This design adds a Drosha processing site to the advantages of microRNA-adapted shRNA with the pGIPZ lentiviral vector to hairpin construct and has been shown to greatly increase gene silencing create a powerful RNA tool capable of producing RNA interference (RNAi) in efficiency (Boden 2004). The hairpin stem consists of 22 nucleotides (nt) of most cell types including primary and non-dividing cells. dsRNA and a 19 nucleotides (nt) loop from human miR-30. Adding the miR-30 loop and 125 nucleotides (nt) of miR-30 flanking sequence on either side of the GIPZ shRNA is available in glycerol stock or viral particle hairpin results in greater than 10-fold increase in Drosha and Dicer processing format. If viral particle format is purchased, begin work with of the expressed hairpins when compared with conventional shRNA designs Protocol IX – Determining Relative Transduction Efficiency. (Silva 2005). Increased Drosha and Dicer processing translates into greater shRNA production and greater potency for expressed hairpins. Important safety note Use of the miR-30 design also allowed the use of ‘rules-based’ designs for target Please follow the safety guidelines for use and production of vector-based sequence selection. One such rule is the destabilizing of the 5' end of the lentivirus as set by your institution’s biosafety committee.
    [Show full text]
  • Top Tips How to Avoid Vector Borne Diseases (Eng)
    Tr a a v r e i ljl s k in a g r e to a Vectors such as mosquitoes, sandflies and HOW tO AvOid ticks can transmit serious infectious diseases both in vEctOR-BORnE the WHO European Region disEAsEs – tOp tips and globally. Many of these vectors are blood sucking and transfer diseases to Take simple measures to protect yourself and your family. human beings through their bites. 1. Before you travel, be vaccinated against diseases prevalent at your destination. vaccines exist for yellow fever, Japanese encephalitis and tick- Avoid being bitten by a borne encephalitis. mosquito, sandfly or tick. 2. consult your doctor, 4–6 weeks before departure if possible, to discuss how you can protect yourself (for example, what antimalarial medicines you Be prepared. should take if malaria is endemic at your destination). 3. Wear light-coloured, long-sleeved shirts and long trousers, tucked into socks or boots, and use insect repellent on exposed skin and clothing to protect yourself from being bitten by mosquitoes, sandflies or ticks. temperature, humidity and the time of day affect the likelihood of being bitten, so know when you need extra protective clothing and insect repellent. 4. Use window screens, if available, to keep mosquitoes outside the place where you are staying. 5. sleep under an insecticide-treated bed net, requesting one if necessary, if you are staying in an area with malaria risk. 6. check your body regularly for ticks. if you find one, remove it with tweezers and apply a skin disinfectant. in tick-infested areas, examine your clothing, luggage and other belongings thoroughly before entering the place where you are staying.
    [Show full text]
  • WHO Factsheet Vector-Borne Diseases
    WHO Factsheet Vector-borne diseases Factsheet # 387 March 2014 KEY FACTS Vector-borne diseases account for more than 17% of all infectious diseases, causing more than 1 million deaths annually. More than 2.5 billion people in over 100 countries are at risk of contracting dengue alone. Malaria causes more than 600 000 deaths every year globally, most of them children under 5 years of age. Other diseases such as Chagas disease, leishmaniasis and schistosomiasis affect hundreds of millions of people worldwide. Many of these diseases are preventable through informed protective measures . Vectors Vectors are living organisms that can transmit infectious diseases between humans or from animals to humans. Many of these vectors are bloodsucking insects, which ingest disease-producing microorganisms during a blood meal from an infected host (human or animal) and later inject it into a new host during their subsequent blood meal. Mosquitoes are the best known disease vector. Others include ticks, flies, sandflies, fleas, triatomine bugs and some freshwater aquatic snails.1 Some main vectors and diseases they transmit VECTORS MAIN DISEASES Mosquitoes Aedes Dengue fever Rift Valley fever Yellow fever Chikungunya Malaria Anopheles Japanese encephalitis Culex Lymphatic filariasis West Nile fever 1 See table Sandflies Leishmaniasis Sandfly fever (phelebotomus fever) Ticks Crimean-Congo haemorrhagic fever Lyme disease Relapsing fever (borreliosis) Rickettsial diseases (spotted fever and Q fever) Tick-borne encephalitis Tularaemia Triatomine bugs Chagas disease (American trypanosomiasis) Tsetse flies Sleeping sickness (African trypanosomiasis) Fleas Plague (transmitted by fleas from rats to humans) Rickettsiosis Black flies Onchocerciasis (river blindness) Aquatic snails Schistosomiasis (bilharziasis) Vector-borne diseases Vector-borne diseases are illnesses caused by pathogens and parasites in human populations.
    [Show full text]
  • Vector Control
    FOR IMMEDIATE RELEASE Contact: Theresa Spinner Director, Media and Public Relations Direct: 202.783.5551 [email protected] Report from the Field: The Impact of COVID-19 on Local Vector Control Activities —As mosquito and tick season approaches, local health departments across the country are limiting vector control activities due to the COVID-19 pandemic — Washington, DC, May 5, 2020 – Today the National Association of County and City Health Officials (NACCHO), representing the country’s nearly 3,000 local health departments, released new data documenting the impact of the COVID-19 response on important vector control programs that protect individuals from mosquito- and tick-borne diseases in communities across the country. The COVID- 19 response has taken time, attention, and personnel away from all other unrelated health priorities, as already-underfunded and understaffed local health departments respond to the pandemic. In doing so, existing services are strained or paused, with health impacts that will ripple through communities. Vector programs are no exception, with program impacts related to staff being pulled to the COVID-19 response, reduced services to comply with social distancing requirements, and curtailed surveillance testing due to laboratory resource constraints. Vector programs in local health departments have been experiencing varying levels of impact from COVID-19 to their routine operations, ranging from minimal impact to entire vector programs being shut down, or large portions of staff being realigned for COVID-19 response activities. Even areas that have experienced outbreaks in vector-borne disease in the past year have had their local vector 2 programs deemed “nonessential” during the COVID-19 pandemic, halting surveillance and control activities that can detect or prevent vector-borne disease threats before they affect the community.
    [Show full text]
  • Control of Sexually Transmitted Infections and Prevention of HIV
    Control of sexually transmitted infections and prevention of HIV transmission: mending a fractured paradigm Richard Steen,a Teodora Elvira Wi,b Anatoli Kamali c & Francis Ndowa d Abstract Control of sexually transmitted infections (STIs) is feasible, leads to improved sexual and reproductive health and contributes to preventing HIV transmission. The most advanced HIV epidemics have developed under conditions of poor STI control, particularly where ulcerative STIs were prevalent. Several countries that have successfully controlled STIs have documented stabilization or reversal of their HIV epidemics. STI control is a public health outcome measured by reduced incidence and prevalence. The means to achieve this include: (i) targeting and outreach to populations at greatest risk; (ii) promoting and providing condoms and other means of prevention; (iii) effective clinical interventions; (iv) an enabling environment; and (v) reliable data. Clinical services include STI case management, screening and management of STIs in sex partners. Syndromic case management is effective for most symptomatic curable STIs and screening strategies exist to detect some asymptomatic infections. Presumptive epidemiologic treatment of sex partners and sex workers complement efforts to interrupt transmission and reduce prevalence. Clinical services alone are insufficient for control since many people with STIs do not attend clinics. Outreach and peer education have been effectively used to reach such populations. STI control requires effective interventions with core populations whose rates of partner change are high enough to sustain transmission. Effective, appropriate targeting is thus necessary and often sufficient to reduce prevalence in the general population. Such efforts are most effective when combined with structural interventions to ensure an enabling environment for prevention.
    [Show full text]